ArticleCanadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the R
Article in Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- RBMJ open · 2021Trial
- Clinical pharmacists' aspirations on prescribing in cardiology within an academic health system.Exploratory research in clinical and social pharmacy · 2026Article
- Rapid Access Atrial Fibrillation Clinics in Australia - Modelling Outcomes and Cost-Effectiveness.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Article
- A model-based cost-effectiveness analysis of prescribing by dietitians and therapeutic radiographers in England.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- [HEARTS Pharmacy: A framework for integrating pharmacists in hypertension and cardiovascular disease risk management in primary careFarmácia HEARTS: um modelo para a integração de farmacêuticos na gestão dos riscos de hipertensão arterial e doenças cardiovasculares na atenção primária].Revista panamericana de salud publica = Pan American journal of public health · 2026Article
- Implementation of Pharmacist Case-Finding and Care Pathway Intervention for Vascular Prevention (PRCJC open · 2025Article
- HEARTS Pharmacy: A framework for integrating pharmacists in hypertension and cardiovascular disease risk management in primary care.Revista panamericana de salud publica = Pan American journal of public health · 2025Article
- Community-Based Pharmacists' Perspectives on Prescribing Authority for the Minor Ailments and Contraception Service in British Columbia.Innovations in pharmacy · 2024Article
- Managing common ambulatory conditions: Exploring clinical decision making performance between pharmacists and family physicians.Exploratory research in clinical and social pharmacy · 2023Article
- Estimating antibiotics consumption in a tertiary care hospital in Islamabad using a WHO's defined daily dose methodology.Antimicrobial resistance and infection control · 2023Article
- Factors Influencing the Implementation of a New Pharmacist Prescribing Service in Community Pharmacies.Pharmacy (Basel, Switzerland) · 2023Article
- Costs, consequences and value for money in non-medical prescribing: a scoping review.BMJ open · 2023Article
- Increased self-reported pharmacist prescribing during the COVID-19 pandemic: Using the Theoretical Domains Framework to identify barriers and facilitators to prescribing.Research in social & administrative pharmacy : RSAP · 2023Article
- Community Pharmacists' Views on the Early Stages of Implementation of a National Pilot Independent Prescribing Service in Wales: A Qualitative Study.Integrated pharmacy research & practice · 2023Article
- Identifying New Zealand Public Preferences for Pharmacist Prescribers in Primary Care: A Discrete Choice Experiment.The patient · 2022Article
- Physicians' views on cardiovascular disease risk prevention services by pharmacists and potential for collaboration.Exploratory research in clinical and social pharmacy · 2021Article
- Examining non-medical prescribing trends in New Zealand: 2016-2020.BMC health services research · 2021Article
- Perceptions of Independent Pharmacist Prescribing among Health Authority- and Community-Based Pharmacists in Northern British Columbia.Pharmacy (Basel, Switzerland) · 2021Article
- Health consumer engagement in developing novel preventive health community pharmacy roles in cardiovascular disease in Saudi Arabia: A qualitative analysis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Article
- Pharmacists and hypertension.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPCArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe R
objectiveTo evaluate the economic impact of pharmacist prescribing and care for CV risk reduction in a Canadian setting.
methodsA Markov cost-effectiveness model was developed to extrapolate potential differences in long-term CV outcomes, using different risk assessment equations. The mean change in CV risk for the 2 groups of R
resultsIt is estimated that the Canadian health care system would save more than $4.4 billion over 30 years if the pharmacist intervention were delivered to 15% of the eligible population. Pharmacist care would be associated with a gain of 576,689 quality-adjusted life years and avoid more than 8.9 million CV events. The intervention is economically dominant (i.e., it is both more effective and reduces costs when compared to usual care).
conclusionAcross a range of 1-way and probabilistic sensitivity analyses of key parameters and assumptions, pharmacist prescribing and care are both more effective and cost-saving compared to usual care. Canadians need and deserve such care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.